Cargando…
P328: CHARACTERIZATION OF A DUX4-R INHIBITOR AS A POSSIBLE TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA
Autores principales: | Salomè, Mara, Campolungo, Daniele, Runfola, Valeria, Pannese, Maria, Carlet, Michela, Caronni, Claudia, Giambruno, Roberto, Ghirardi, Chiara, Jeremias, Irmela, Gabellini, Davide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428239/ http://dx.doi.org/10.1097/01.HS9.0000968224.47489.ef |
Ejemplares similares
-
MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy
por: Runfola, Valeria, et al.
Publicado: (2023) -
DUX4 Role in Normal Physiology and in FSHD Muscular Dystrophy
por: Mocciaro, Emanuele, et al.
Publicado: (2021) -
WDR5 is required for DUX4 expression and its pathological effects in FSHD muscular dystrophy
por: Mocciaro, Emanuele, et al.
Publicado: (2023) -
Efficient RNA interference in patients' acute lymphoblastic leukemia cells amplified as xenografts in mice
por: Höfig, Ines, et al.
Publicado: (2012) -
Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia
por: Li, Zhenhua, et al.
Publicado: (2021)